Group News

Johannesburg – JSE listed Aspen (Apn), Africa’s largest pharmaceutical manufacturer, has announced impressive results for the financial year ended June 30, 2006. These are the first set of annual results reported under International Financial Reporting Standards (IFRS). Headline earnings per share (HEPS) grew by 235 percent to 185.5 cents (144.7 cents). Revenue increased by 23…

Aspen was ranked third in the June 2006 Financial Mail Top Companies survey. Companies are ranked based on consistent performance for five years. Aspen wasn’t on the radar screen a few years ago; now it’s in third position and has a market capitalization in excess of R14 billion. Aspen’s share delivered a highly credible 112%…

Aspen (APN), South Africa’s largest listed pharmaceutical company, today announced that it has reached an agreement with Roche to produce a generic version of oseltamivir for Africa. This complements Roche’s continued efforts to increase and speed up availability of the medicine for world wide influenza pandemic planning. The agreement focuses on providing oseltamivir for pandemic…

Johannesburg – JSE listed Aspen (APN) and Indian based Lupin Limited have entered into a Memorandum of Understanding for the establishment of a 50:50 joint venture for the development, manufacture and global marketing of selected anti-tuberculosis (TB) products. The JV will also investigate opportunities to enter the Malaria market. Stephen Saad, Aspen Group Chief Executive…

Aspen records 45% increase in HEPS Johannesburg – JSE listed Aspen (Apn), Africa’s largest pharmaceutical manufacturer, has recorded impressive interim results for the period ended December 2005. Headline earnings per share (HEPS) increased 45 percent to 86.3 cents (59.4 cents). Revenue increased by 27 percent to R1,687 billion (R1.4 billion). Operating profit rose 34 percent…

JSE listed Aspen Pharmacare Holdings Limited, Africa’s largest pharmaceutical manufacturer and the largest generic manufacturer in the southern hemisphere, has signed a non-exclusive license and technology transfer collaboration agreement with New York based Bristol-Myers Squibb (BMS) for the manufacture and distribution of a generic version of Atazanavir, a new generation anti-retroviral (ARV). BMS selected Aspen…

Former President Clinton Announces New Agreements to Lower Prices of HIV/AIDS Rapid Tests and Second-Line Drugs Agreements with Nine Companies Will Lower Prices of HIV Diagnosis and Two HIV/AIDS Medicines by 30-50 Percent for 50 Countries Clinton Also Confirms that Nearly a Quarter-Million People Living with HIV are Benefiting from First-Line HIV/AIDS Drug Agreements his…

JSE listed Aspen Pharmacare, Africa’s largest pharmaceutical manufacturer and the leading global player in generic anti-retrovirals (ARVs), earlier today opened a R1 million wellness centre in the Eastern Cape. Through a public-private partnership, Aspen’s investment in the establishment of the Wells Estate Wellness Centre will enhance the primary healthcare services at the Nelson Mandela Bay…

JSE listed Aspen Pharmacare Holdings Limited and Lupin Limited of India have entered into an agreement to collaborate in the tuberculosis (TB) related products market in South Africa. The agreement involves cooperation in the areas of technology, manufacture and marketing. Stephen Saad, Aspen Group Chief Executive said, “the agreement enhances South Africa and Aspen’s ability…